Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.56 |
| ▸ | HMGCR | P04035 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015878 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9836895 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015933 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015881 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015929 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL514093 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9943966 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9015897 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL512606 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL512382 | 1.00 | PTPN7 (0.56) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2024211865-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | OMEGA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-3642211-B1 | ALDIMINOSILANES | SIKA TECH AG (CH) | 2023-04-05 | — | — | EP | claimed |
| EP-3642252-B1 | LATENT CURING AGENT AND CURABLE POLYURETHANE COMPOSITION | SIKA TECH AG (CH) | 2021-12-08 | — | — | EP | claimed |
| EP-2181763-B1 | Catalyst and process for alkoxylation | SHELL INT RESEARCH (NL) | 2012-06-20 | — | — | EP | claimed |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211865-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | OMEGA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023225621-A2 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | OMEGA THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-102342288-A | Pest control composition | SUMITOMO CHEMICAL CO | 2012-02-08 | — | — | CN | disclosed |
| EP-0748823-A1 | Catalyst composition and process for the production of olefinic polymers | NIPPON OIL CO. LTD. (JP) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | NSUN3, NSUN2, LDLR | PTPN7 2194/4885HMGCR 460/4885RECQL 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.